JÃ³zsÃ©f A TÃ¶zsÃ©r

List of Publications by Year
in descending order

148 papers	5,264 citations	87888 38 h-index	102487 66 g-index
148 all docs	148 docs citations	148 times ranked	6007 citing authors

#	Article	IF	Citations
1	Fast and Sensitive Quantification of AccQ-Tag Derivatized Amino Acids and Biogenic Amines by UHPLC-UV Analysis from Complex Biological Samples. Metabolites, 2022, 12, 272.	2.9	10
2	Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease. International Journal of Molecular Sciences, 2022, 23, 3507.	4.1	45
3	Metabolomic Analysis of Serum and Tear Samples from Patients with Obesity and Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 2022, 23, 4534.	4.1	10
4	Chemical Barrier Proteins in Human Body Fluids. Biomedicines, 2022, 10, 1472.	3.2	2
5	Defective binding of SPINK1 variants is an uncommon mechanism for impaired trypsin inhibition in chronic pancreatitis. Journal of Biological Chemistry, 2021, 296, 100343.	3.4	15
6	Biochemical Characterization, Specificity and Inhibition Studies of HTLV-1, HTLV-2, and HTLV-3 Proteases. Life, 2021, 11, 127.	2.4	10
7	Specificity of the HIV-1 Protease on Substrates Representing the Cleavage Site in the Proximal Zinc-Finger of HIV-1 Nucleocapsid Protein. Viruses, 2021, 13, 1092.	3.3	1
8	Effect of Inducible BMP-7 Expression on the Osteogenic Differentiation of Human Dental Pulp Stem Cells. International Journal of Molecular Sciences, 2021, 22, 6182.	4.1	7
9	Development of a Bio-Layer Interferometry-Based Protease Assay Using HIV-1 Protease as a Model. Viruses, 2021, 13, 1183.	3.3	7
10	Reduced Level of Tear Antimicrobial and Immunomodulatory Proteins as a Possible Reason for Higher Ocular Infections in Diabetic Patients. Pathogens, 2021, 10, 883.	2.8	2
11	Cellular Proteo-Transcriptomic Changes in the Immediate Early-Phase of Lentiviral Transduction. Microorganisms, 2021, 9, 2207.	3.6	4
12	Biochemical characterization of Ty1 retrotransposon protease. PLoS ONE, 2020, 15, e0227062.	2.5	9
13	Effect of inducible bone morphogenetic protein 2 expression on the osteogenic differentiation of dental pulp stem cells in vitro. Bone, 2020, 132, 115214.	2.9	24
14	Biochemical Characterization of Human Retroviral-Like Aspartic Protease 1 (ASPRV1). Biomolecules, 2020, 10, 1004.	4.0	4
15	Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2â€²s main protease. Virology Journal, 2020, 17, 190.	3.4	73
16	Study of the Retrotransposon-Derived Human PEG10 Protease. Proceedings (mdpi), 2020, 50, 110.	0.2	0
17	Y44A Mutation in the Acidic Domain of HIV-2 Tat Impairs Viral Reverse Transcription and LTR-Transactivation. International Journal of Molecular Sciences, 2020, 21, 5907.	4.1	0
18	Examination of Oral Squamous Cell Carcinoma and Precancerous Lesions Using Proximity Extension Assay and Salivary RNA Quantification. Biomedicines, 2020, 8, 610.	3.2	4

#	Article	IF	Citations
19	Identification of Host Cellular Protein Substrates of SARS-COV-2 Main Protease. International Journal of Molecular Sciences, 2020, 21, 9523.	4.1	22
20	Compounds with Antiviral, Anti-Inflammatory and Anticancer Activity Identified in Wine from Hungaryâ€™s Tokaj Region via High Resolution Mass Spectrometry and Bioinformatics Analyses. International Journal of Molecular Sciences, 2020, 21, 9547.	4.1	9
21	Specificity Studies of the Venezuelan Equine Encephalitis Virus Non-Structural Protein 2 Protease Using Recombinant Fluorescent Substrates. International Journal of Molecular Sciences, 2020, 21, 7686.	4.1	6
22	Elucidating the Role of HIV-2 Viral Protein X. Proceedings (mdpi), 2020, 50, 24.	0.2	0
23	Dimer Interface Organization is a Main Determinant of Intermonomeric Interactions and Correlates with Evolutionary Relationships of Retroviral and Retroviral-Like Ddi1 and Ddi2 Proteases. International Journal of Molecular Sciences, 2020, 21, 1352.	4.1	10
24	Functional Study of the Retrotransposon-Derived Human PEG10 Protease. International Journal of Molecular Sciences, 2020, 21, 2424.	4.1	16
25	Analysis of networks of host proteins in the early time points following HIV transduction. BMC Bioinformatics, 2019, 20, 398.	2.6	10
26	Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation. Journal of Visualized Experiments, 2019, , .	0.3	7
27	Comparative analysis of cytokine profiles of glaucomatous tears and aqueous humour reveals potential biomarkers for trabeculectomy complications. FEBS Open Bio, 2019, 9, 1020-1028.	2.3	19
28	Salivary IL-6 mRNA is a Robust Biomarker in Oral Squamous Cell Carcinoma. Journal of Clinical Medicine, 2019, 8, 1958.	2.4	19
29	Salivary proteome profiling of oral squamous cell carcinoma in a Hungarian population. FEBS Open Bio, 2018, 8, 556-569.	2.3	18
30	A recombinant fusion protein-based, fluorescent protease assay for high throughput-compatible substrate screening. Analytical Biochemistry, 2018, 540-541, 52-63.	2.4	10
31	Wound-Healing Markers Revealed by Proximity Extension Assay in Tears of Patients following Glaucoma Surgery. International Journal of Molecular Sciences, 2018, 19, 4096.	4.1	13
32	Data supporting Ni-NTA magnetic bead-based fluorescent protease assay using recombinant fusion protein substrates. Data in Brief, 2018, 18, 203-208.	1.0	9
33	Inhibitory Effects of HIV-2 Vpx on Replication of HIV-1. Journal of Virology, 2018, 92, .	3.4	5
34	Diabetic retinopathy: Proteomic approaches to help the differential diagnosis and to understand the underlying molecular mechanisms. Journal of Proteomics, 2017, 150, 351-358.	2.4	32
35	Different dynamics of NLRP3 inflammasome-mediated IL-1Î² production in GM-CSFâ€“ and M-CSFâ€“differentiated human macrophages. Journal of Leukocyte Biology, 2017, 101, 1335-1347.	3.3	23
36	The proteomic profile of a mouse model of proliferative vitreoretinopathy. FEBS Open Bio, 2017, 7, 1166-1177.	2.3	8

#	Article	IF	Citations
37	Quantitative body fluid proteomics in medicine â€" A focus on minimal invasiveness. Journal of Proteomics, 2017, 153, 30-43.	2.4	62
38	Plasminogen activator activity in tears of pregnant women. PLoS ONE, 2017, 12, e0177003.	2.5	4
39	Proteomics investigation of OSCC-specific salivary biomarkers in a Hungarian population highlights the importance of identification of population-tailored biomarkers. PLoS ONE, 2017, 12, e0177282.	2.5	54
40	Proteomic analysis of protein phosphatase Z1 from Candida albicans. PLoS ONE, 2017, 12, e0183176.	2.5	10
41	Natural Compounds as Regulators of NLRP3 Inflammasome-Mediated IL-1Î²Production. Mediators of Inflammation, 2016, 2016, 1-16.	3.0	104
42	Changes in the Chemical Barrier Composition of Tears in Alzheimerâ€™s Disease Reveal Potential Tear Diagnostic Biomarkers. PLoS ONE, 2016, 11, e0158000.	2.5	94
43	Effect of internal cleavage site mutations in human immunodeficiency virus type 1 capsid protein on its structure and function. FEBS Open Bio, 2016, 6, 847-859.	2.3	2
44	Relative quantification of human Î²â€defensins by a proteomics approach based on selected reaction monitoring. Rapid Communications in Mass Spectrometry, 2015, 29, 1623-1631.	1.5	6
45	Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System. Viruses, 2015, 7, 6152-6162.	3.3	13
46	Combined Methods for Diabetic Retinopathy Screening, Using Retina Photographs and Tear Fluid Proteomics Biomarkers. Journal of Diabetes Research, 2015, 2015, 1-8.	2.3	35
47	A Modular System to Evaluate the Efficacy of Protease Inhibitors against HIV-2. PLoS ONE, 2014, 9, e113221.	2.5	5
48	Differential temperature dependence of tobacco etch virus and rhinovirus 3C proteases. Analytical Biochemistry, 2013, 436, 142-144.	2.4	22
49	Enhanced Stability of Monomer Fold Correlates with Extreme Drug Resistance of HIV-1 Protease. Biochemistry, 2013, 52, 7678-7688.	2.5	9
50	Aloe vera downregulates LPS-induced inflammatory cytokine production and expression of NLRP3 inflammasome in human macrophages. Molecular Immunology, 2013, 56, 471-479.	2.2	137
51	A molecular model of the full-length human NOD-like receptor family CARD domain containing 5 (NLRC5) protein. BMC Bioinformatics, 2013, 14, 275.	2.6	27
52	Tear fluid proteomics multimarkers for diabetic retinopathy screening. BMC Ophthalmology, 2013, 13, 40.	1.4	47
53	Equine Infectious Anemia Virus Retropepsin. , 2013, , 207-210.		0
54	Bovine Leukemia Virus Retropepsin. , 2013, , 218-220.		1

#	Article	IF	Citations
55	Mouse Mammary Tumor Virus Retropepsin. , 2013, , 223-226.		0
56	Moloney Murine Leukemia Virus Retropepsin. , 2013, , 226-230.		0
57	Ragweed pollen extract intensifies lipopolysaccharideâ€induced priming of <scp>NLRP</scp>3 inflammasome in human macrophages. Immunology, 2013, 138, 392-401.	4.4	26
58	Research Applications of Proteolytic Enzymes in Molecular Biology. Biomolecules, 2013, 3, 923-942.	4.0	171
59	Inhibition of XMRV and HIVâ€1 proteases by pepstatin A and acetylâ€pepstatin. FEBS Journal, 2012, 279, 3276-3286.	4.7	8
60	Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. Journal of Proteomics, 2012, 75, 2196-2204.	2.4	113
61	Critical differences in HIVâ€1 and HIVâ€2 protease specificity for clinical inhibitors. Protein Science, 2012, 21, 339-350.	7.6	38
62	The substrate specificity of Metarhizium anisopliae and Bos taurus carboxypeptidases A: Insights into their use as tools for the removal of affinity tags. Protein Expression and Purification, 2011, 77, 53-61.	1.3	11
63	Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virusâ€related virus protease. FEBS Journal, 2011, 278, 4413-4424.	4.7	8
64	Structural determinants of tobacco vein mottling virus protease substrate specificity. Protein Science, 2010, 19, 2240-2251.	7.6	28
65	Comparative Studies on Retroviral Proteases: Substrate Specificity. Viruses, 2010, 2, 147-165.	3.3	41
66	Urokinase Down-Regulation by Aprotinin in Rabbit Corneal Cells After Photorefractive Keratectomy. Current Eye Research, 2010, 35, 806-811.	1.5	1
67	Discovery and significance of new human T-lymphotropic viruses: HTLV-3 and HTLV-4. Expert Review of Anti-Infective Therapy, 2009, 7, 1235-1249.	4.4	12
68	HIV-1 Protease and AIDS Therapy. , 2009, , 25-45.		3
69	Regulation of calpain B from Drosophila melanogaster by phosphorylation. FEBS Journal, 2009, 276, 4959-4972.	4.7	7
70	Molecular cloning, overproduction, purification and biochemical characterization of the p39 nsp2 protease domains encoded by three alphaviruses. Protein Expression and Purification, 2009, 64, 89-97.	1.3	23
71	Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection. Infectious Disorders - Drug Targets, 2009, 9, 159-171.	0.8	6
72	Plasminogen activator inhibitor in human tears after laser refractive surgery. Journal of Cataract and Refractive Surgery, 2008, 34, 897-901.	1.5	17

#	Article	IF	Citations
73	HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends in Pharmacological Sciences, 2008, 29, 42-49.	8.7	51
74	Amino Acid Preferences of Retroviral Proteases for Amino-Terminal Positions in a Type 1 Cleavage Site. Journal of Virology, 2008, 82, 10111-10117.	3.4	23
75	Novel macromolecular inhibitors of human immunodeficiency virus-1 protease. Protein Engineering, Design and Selection, 2008, 21, 453-461.	2.1	9
76	C-terminal residues of mature human T-lymphotropic virus typeÂ1 protease are critical for dimerization and catalytic activity. Biochemical Journal, 2008, 416, 357-364.	3.7	13
77	Constitutive and UV-B modulated transcription of Nod-like receptors and their functional partners in human corneal epithelial cells. Molecular Vision, 2008, 14, 1575-83.	1.1	25
78	The Protease of Human T-Cell Leukemia Virus Type-1 is a Potential Therapeutic Target. Current Pharmaceutical Design, 2007, 13, 1285-1294.	1.9	20
79	Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases. Journal of General Virology, 2007, 88, 2052-2063.	2.9	17
80	HIV-1 Protease Dimer Interface Mutations that Compensate for Viral Reverse Transcriptase Instability in Infectious Virions. Journal of Molecular Biology, 2007, 372, 369-381.	4.2	14
81	Potent New Antiviral Compound Shows Similar Inhibition and Structural Interactions with Drug Resistant Mutants and Wild Type HIV-1 Proteaseâ€. Journal of Medicinal Chemistry, 2007, 50, 4509-4515.	6.4	40
82	Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins: Structure, Function and Bioinformatics, 2007, 67, 232-242.	2.6	84
83	Effect of experimental hypercholesterolaemia on K+ channel Î±-subunit mRNA levels in rabbit hearts. European Journal of Pharmacology, 2007, 562, 130-131.	3.5	6
84	Structural and Kinetic Analysis of Caspase-3 Reveals Role for S5 Binding Site in Substrate Recognition. Journal of Molecular Biology, 2006, 360, 654-666.	4.2	62
85	Improved purification protocol for wild-type and mutant human foamy virus proteases. Protein Expression and Purification, 2006, 46, 343-347.	1.3	5
86	Synthesis, Processing, and Composition of the Virion-associated HTLV-1 Reverse Transcriptase. Journal of Biological Chemistry, 2006, 281, 3964-3971.	3.4	11
87	Replication-dependent fitness recovery of Human immunodeficiency virus 1 harbouring mutations of Asn17 of the nucleocapsid protein. Journal of General Virology, 2006, 87, 961-965.	2.9	2
88	Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease. Journal of General Virology, 2006, 87, 1321-1330.	2.9	20
89	Effect of mutations on the dimer stability and the pH optimum of the human foamy virus protease. Protein Engineering, Design and Selection, 2006, 19, 369-375.	2.1	3
90	Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3086-3090.	2.2	141

#	Article	IF	Citations
91	Comparison of the substrate specificity of two potyvirus proteases. FEBS Journal, 2005, 272, 514-523.	4.7	40
92	Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 A resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS Journal, 2005, 272, 5265-5277.	4.7	71
93	Amino Acid Preferences for a Critical Substrate Binding Subsite of Retroviral Proteases in Type 1 Cleavage Sites. Journal of Virology, 2005, 79, 4213-4218.	3.4	37
94	Kinetic, Stability, and Structural Changes in High-resolution Crystal Structures of HIV-1 Protease with Drug-resistant Mutations L24I, I50V, and G73S. Journal of Molecular Biology, 2005, 354, 789-800.	4.2	68
95	Molecular Modeling of Nearly Full-Length ErbB2 Receptor. Biophysical Journal, 2005, 88, 1354-1363.	0.5	36
96	Narrow Substrate Specificity and Sensitivity toward Ligand-binding Site Mutations of Human T-cell Leukemia Virus Type 1 Protease. Journal of Biological Chemistry, 2004, 279, 27148-27157.	3.4	45
97	Urokinase-Type Plasminogen Activator to Prevent Haze after Photorefractive Keratectomy, and Pregnancy as a Risk Factor for Haze in Rabbits. Investigative Ophthalmology and Visual Science, 2004, 45, 1329-1333.	3.3	11
98	Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. FEBS Journal, 2004, 271, 1516-1524.	0.2	71
99	Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. Journal of Virological Methods, 2004, 119, 87-93.	2.1	35
100	In Vitro Processing of HIV-1 Nucleocapsid Protein by the Viral Proteinase:â€‰ Effects of Amino Acid Substitutions at the Scissile Bond in the Proximal Zinc Finger Sequence. Biochemistry, 2004, 43, 4304-4312.	2.5	5
101	Expression of the murine leukemia virus protease in fusion with maltose-binding protein in Escherichia coli. Protein Expression and Purification, 2004, 35, 62-68.	1.3	13
102	Efficient site-specific processing of fusion proteins by tobacco vein mottling virus protease in vivo and in vitro. Protein Expression and Purification, 2004, 38, 108-115.	1.3	125
103	Moloney murine leukemia virus retropepsin. , 2004, , 176-178.		2
104	Equine infectious anemia virus retropepsin. , 2004, , 160-163.		0
105	Human immunodeficiency virus type 1 capsid protein is a substrate of the retroviral proteinase while integrase is resistant toward proteolysis. Virology, 2003, 310, 16-23.	2.4	14
106	Plasminogen activator activity and inhibition in rabbit tears after photorefractive keratectomy. Experimental Eye Research, 2003, 77, 675-680.	2.6	12
107	Proteolytic Events of HIV-1 Replication as Targets for Therapeutic Intervention. Current Pharmaceutical Design, 2003, 9, 1803-1815.	1.9	31
108	Effect of caspase cleavage-site phosphorylation on proteolysis. Biochemical Journal, 2003, 372, 137-143.	3.7	45

#	Article	IF	Citations
109	Stages of HIV Replication and Targets for Therapeutic Intervention. Current Topics in Medicinal Chemistry, 2003, 3, 1447-1457.	2.1	13
110	The P1â€² specificity of tobacco etch virus protease. Biochemical and Biophysical Research Communications, 2002, 294, 949-955.	2.1	331
111	Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. FEBS Journal, 2002, 269, 4114-4120.	0.2	64
112	Combining mutations in HIV-1 protease to understand mechanisms of resistance. Proteins: Structure, Function and Bioinformatics, 2002, 48, 107-116.	2.6	46
113	Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Engineering, Design and Selection, 2001, 14, 993-1000.	2.1	729
114	HIV Inhibitors: Problems and Reality. Annals of the New York Academy of Sciences, 2001, 946, 145-159.	3.8	39
115	Folded Monomer of HIV-1 Protease. Journal of Biological Chemistry, 2001, 276, 49110-49116.	3.4	85
116	Clustering of Class I HLA Oligomers with CD8 and TCR: Three-Dimensional Models Based on Fluorescence Resonance Energy Transfer and Crystallographic Data. Journal of Immunology, 2001, 166, 5078-5086.	0.8	41
117	Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases. FEBS Journal, 2000, 267, 6287-6295.	0.2	59
118	Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase. BBA - Proteins and Proteomics, 2000, 1478, 1-8.	2.1	16
119	HIV-I protease: Maturation, enzyme specificity, and drug resistance. Advances in Pharmacology, 2000, 49, 111-146.	2.0	67
120	Stabilization from Autoproteolysis and Kinetic Characterization of the Human T-cell Leukemia Virus Type 1 Proteinase. Journal of Biological Chemistry, 1999, 274, 6660-6666.	3.4	52
121	Effect of substrate residues on the P2' preference of retroviral proteinases. FEBS Journal, 1999, 264, 921-929.	0.2	37
122	Effect of serine and tyrosine phosphorylation on retroviral proteinase substrates. FEBS Journal, 1999, 265, 423-429.	0.2	14
123	Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. Archives of Virology, 1999, 144, 2151-2160.	2.1	32
124	Improved Parameters for Generating Partial Charges: Correlation with Observed Dipole Moments. Journal of Molecular Modeling, 1999, 5, 143-152.	1.8	18
125	Molecular mechanism of the short-term cardiotoxicity caused by 2â€²,3â€²-dideoxycytidine (ddC): modulation of reactive oxygen species levels and ADP-ribosylation reactions. Biochemical Pharmacology, 1999, 58, 1915-1925.	4.4	47
126	Expression and characterization of human foamy virus proteinase. FEBS Letters, 1999, 462, 397-401.	2.8	19

#	Article	IF	Citations
127	Lactate dehydrogenase activity in pathological human tears obtained with glass capillaries correlates with the albumin content. , 1998, 22, 289-292.		6
128	Transforming Growth Factor-Î² Induced Protein, Î²IG-H3, is Present in Degraded Form and Altered Localization in Lattice Corneal Dystrophy Type I. Experimental Eye Research, 1998, 66, 739-745.	2.6	31
129	Studies on the Symmetry and Sequence Context Dependence of the HIV-1 Proteinase Specificity. Journal of Biological Chemistry, 1997, 272, 16807-16814.	3.4	35
130	Activity of Tethered Human Immunodeficiency Virus 1 Protease Containing Mutations in the Flap Region of One Subunit. FEBS Journal, 1997, 244, 235-241.	0.2	19
131	Specificity of retroviral proteinases based on substrates containing tyrosine and proline at the site of cleavage. Pathology and Oncology Research, 1997, 3, 142-146.	1.9	8
132	Soluble cell-bound and extracellular cyclodextrin glycosyltransferases ofBacillus macerans show identical enzymological characteristics and antigenicity. Journal of Basic Microbiology, 1996, 36, 335-340.	3.3	4
133	NADP-specific glutamate dehydrogenase ofPenicillium chrysogenum has a homohexamer structure. Journal of Basic Microbiology, 1996, 36, 371-375.	3.3	9
134	Comparative Studies on the Substrate Specificity of Avian Myeloblastosis Virus Proteinase and Lentiviral Proteinases. Journal of Biological Chemistry, 1996, 271, 6781-6788.	3.4	29
135	Activity of linked HIV-1 proteinase dimers containing mutations in the active site region. Protein Engineering, Design and Selection, 1996, 9, 997-1003.	2.1	11
136	Molecular model of equine infectious anemia virus proteinase and kinetic measurements for peptide substrates with single amino acid substitutions. Biochemistry, 1993, 32, 3354-3362.	2.5	21
137	Studies on the substrate specificity of the proteinase of equine infectious anemia virus using oligopeptide substrates. Biochemistry, 1993, 32, 3347-3353.	2.5	40
138	Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. Biochemistry, 1992, 31, 4793-4800.	2.5	113
139	Solid phase synthesis of the proteinase of bovine leukemia virus Comparison of its specificity to that of HIV-2 proteinase. FEBS Letters, 1992, 309, 389-393.	2.8	22
140	Studies on the role of the S4substrate binding site of HIV proteinases. FEBS Letters, 1991, 279, 356-360.	2.8	71
141	Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Letters, 1991, 281, 77-80.	2.8	164
142	Tear plasminogen activators ? indicators of epithelial cell destruction. The effect of scraping, n-heptanol debridement, and alkali burn of the cornea on the plasminogen activator activity of rabbit tears. International Ophthalmology, 1991, 15, 363-369.	1.4	4
143	Synthesis of homologous peptides using fragment condensation: analogs of an HIV proteinase substrate. International Journal of Peptide and Protein Research, 1991, 38, 453-458.	0.1	16
144	Plasminogen activator inhibitors in human tears. Acta Ophthalmologica, 1991, 69, 426-431.	1.1	9

#	Article	IF	Citations
145	Urokinase-type plasminogen activator in rabbit tears. Comparison with human tears. Experimental Eye Research, 1990, 51, 33-37.	2.6	10
146	Substitution of proline with pipecolic acid at the scissile bond converts a peptide substrate of HIV proteinase into a selective inhibitor. Biochemical and Biophysical Research Communications, 1990, 169, 310-314.	2.1	73
147	Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva. Acta Ophthalmologica, 1990, 68, 508-514.	1.1	27
148	Plasminogen activator activity and plasminogen independent amidolytic activity in tear fluid from healthy persons and patients with anterior segment inflammation. Clinica Chimica Acta, 1989, 183, 323-331.	1.1	18